{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:27:43Z","timestamp":1778092063366,"version":"3.51.4"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The licensed anthrax vaccine and many of the new anthrax vaccines being developed are based on protective antigen (PA), a nontoxic component of anthrax toxin. For this reason, an understanding of the immune response to PA vaccination is important. In this study, we examined the antibody response elicited by PA-based vaccines and identified the domains of PA that contribute to that response in humans as well as nonhuman primates (NHPs) and rabbits, animal species that will be used to generate efficacy data to support approval of new anthrax vaccines. To this end, we developed a competitive enzyme-linked immunosorbent assay (ELISA), using purified recombinant forms of intact PA and its individual domains. We found that PA-based vaccines elicited IgG antibodies to each of the four PA domains in all three species. We also developed a competitive toxin neutralization assay, which showed that rabbits, NHPs, and humans all have functional antibody populations that bind to domains 1, 3, and 4. While the domain specificities of the antibody responses elicited by PA-based vaccines were similar in humans, NHPs, and rabbits, competitive assays suggested that humans may have a more significant secondary population of IgG antibodies that bind to partially unfolded or incorrectly folded PA. These findings provide information that will be useful when linking animal protection data to humans via an antibody bridge to establish efficacy of new anthrax vaccines.<\/jats:p>","DOI":"10.1128\/cvi.00145-10","type":"journal-article","created":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T03:46:59Z","timestamp":1279165619000},"page":"1390-1397","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Analysis of Antibody Responses to Protective Antigen-Based Anthrax Vaccines through Use of Competitive Assays"],"prefix":"10.1128","volume":"17","author":[{"given":"Rebecca A.","family":"Brady","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Verma","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Meade","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drusilla L.","family":"Burns","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"},{"name":"Meade Biologics, Hillsborough, North Carolina 27278"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00015-08"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1365-2672.2006.03112.x","volume":"101","year":"2006","unstructured":"Baillie, L. W. J. 2006. Past, imminent and future human medical countermeasures for anthrax. J. Appl. Microbiol.101:594-606.","journal-title":"J. Appl. Microbiol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","volume":"19","year":"2003","unstructured":"Collier, R. J., and J. A. T. Young. 2003. Anthrax toxin. Annu. Rev. Cell Dev. Biol.19:45-70.","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199909093411107","volume":"341","year":"1999","unstructured":"Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med.341:815-826.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_6_2","unstructured":"Transcripts of Workshop Anthrax Vaccines: Efficacy Testing and Surrogate Markers of Immunity. 2002"},{"key":"e_1_3_2_7_2","unstructured":"Transcripts of Workshop Anthrax: Bridging Correlates of Protection in Animals to Immunogenicity in Humans. 2007"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","volume":"19","year":"2001","unstructured":"Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. M. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine19:3241-3247.","journal-title":"Vaccine"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.4.2022-2028.2002"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.3.1653-1656.2002"},{"key":"e_1_3_2_11_2","first-page":"33","volume":"271","year":"2002","unstructured":"Friedlander, A. M., S. L. Welkos, and B. E. Ivins. 2002. Anthrax vaccines. Curr. Top. Microbiol. Immunol.271:33-60.","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.1.82-87.1995"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1086\/523578","volume":"46","year":"2008","unstructured":"Grabenstein, J. D. 2008. Vaccines: countering anthrax: vaccines and immunoglobulins. Clin. Infect. Dis.46:129-136.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","volume":"13","year":"1995","unstructured":"Ivins, B., P. Fellows, L. Pitt, J. Estep, J. Farchaus, A. Friedlander, and P. Gibbs. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine13:1779-1784.","journal-title":"Vaccine"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","volume":"8","year":"2002","unstructured":"Jernigan, D. B., P. L. Raghunathan, B. P. Bell, R. Brechner, E. A. Bresnitz, J. C. Butler, M. Cetron, M. Cohen, T. Doyle, M. Fischer, C. Greene, K. S. Griffith, J. Guarner, J. L. Hadler, J. A. Hayslett, R. Meyer, L. R. Petersen, M. Phillips, R. Pinner, T. Popovic, C. P. Quinn, J. Reefhuis, D. Reissman, N. Rosenstein, A. Schuchat, W. J. Shieh, L. Siegal, D. L. Swerdlow, F. C. Tenover, M. Traeger, J. W. Ward, I. Weisfuse, S. Wiersma, K. Yeskey, S. Zaki, D. A. Ashford, B. A. Perkins, S. Ostroff, J. Hughes, D. Fleming, J. P. Koplan, and J. L. Gerberding. 2002. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg. Infect. Dis.8:1019-1028.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1073\/pnas.0405405101","volume":"101","year":"2004","unstructured":"Lacy, D. B., D. J. Wigelsworth, R. A. Melnyk, S. C. Harrison, and R. J. Collier. 2004. Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc. Nat. Acad. Sci. U. S. A.101:13147-13151.","journal-title":"Proc. Nat. Acad. Sci. U. S. A."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1099\/13500872-142-3-707","volume":"142","year":"1996","unstructured":"Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology142:707-715.","journal-title":"Microbiology"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0022-2836(70)90051-3","volume":"53","year":"1970","unstructured":"Mandel, M., and A. Higa. 1970. Calcium-dependent bacteriophage DNA infection. J. Mol. Biol.53:159-162.","journal-title":"J. Mol. Biol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1472-765X.1998.00274.x","volume":"26","year":"1998","unstructured":"Miller, J., B. W. McBride, R. J. Manchee, P. Moore, and L. W. Baillie. 1998. Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Lett. Appl. Microbiol.26:56-60.","journal-title":"Lett. Appl. Microbiol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0022-1759(93)90223-T","volume":"158","year":"1993","unstructured":"Ngai, P. K., F. Ackermann, H. Wendt, R. Savoca, and H. R. Bosshard. 1993. Protein A antibody-capture ELISA (PACE): an ELISA format to avoid denaturation of surface-adsorbed antigens. J. Immunol. Methods158:267-276.","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/385833a0","volume":"385","year":"1997","unstructured":"Petosa, C., R. J. Collier, K. R. Klimpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature385:833-838.","journal-title":"Nature"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.68.4.617-629.2004"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","volume":"87","year":"1999","unstructured":"Pitt, M. L. M., S. Little, B. E. Ivins, P. Fellows, J. Boles, J. Barth, J. Hewetson, and A. M. Friedlander. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol.87:304.","journal-title":"J. Appl. Microbiol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","volume":"20","year":"2001","unstructured":"Pittman, P. R., P. H. Gibbs, T. L. Cannon, and A. M. Friedlander. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine20:972-978.","journal-title":"Vaccine"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01254-08"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1016\/j.vaccine.2008.05.023","volume":"26","year":"2008","unstructured":"Reason, D. C., A. Ullal, J. Liberato, J. Sun, W. Keitel, and J. Zhou. 2008. Domain specificity of the human antibody response to Bacillus anthracis protective antigen. Vaccine26:4041-4047.","journal-title":"Vaccine"},{"key":"e_1_3_2_27_2","first-page":"99","volume":"110","year":"2002","unstructured":"Rosenthal, S. R., and J. C. Clifford. 2002. Development of vaccines for bio-warfare agents. Dev. Biol. (Basel)110:99-105.","journal-title":"Dev. Biol. (Basel)"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-1759(12)80037-8","volume":"147","year":"1992","unstructured":"Schwab, C., and H. R. Bosshard. 1992. Caveats for the use of surface-adsorbed protein antigen to test the specificity of antibodies. J. Immunol. Methods147:125-134.","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00194-09"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.9.5978-5987.2005"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.molimm.2007.06.159","volume":"45","year":"2008","unstructured":"Zhou, J., A. Ullal, J. Liberato, J. Sun, W. Keitel, and D. C. Reason. 2008. Paratope diversity in the human antibody response to Bacillus anthracis protective antigen. Mol. Immunol.45:338-347.","journal-title":"Mol. Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00145-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00145-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:44:09Z","timestamp":1627591449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00145-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1128\/CVI.00145-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00145-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"2010-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-06-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}